A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

(Animal Ethics: Not required; Human Ethics: N/A (Ethics remains through Alfred as per head agreement); Gene Tech: Not required; Biosafety/Radiation: No; Split Grants: N/A)
Effective start/end date13/09/2131/12/24


  • Solid tumours
  • Oncology
  • Clinical trial